Dennis Lo

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1794850/publications.pdf

Version: 2024-02-01

2544 3650 35,908 325 96 180 citations h-index g-index papers 336 336 336 21392 citing authors docs citations times ranked all docs

#	Article	IF	CITATIONS
1	Presence of fetal DNA in maternal plasma and serum. Lancet, The, 1997, 350, 485-487.	13.7	2,657
2	Quantitative Analysis of Fetal DNA in Maternal Plasma and Serum: Implications for Noninvasive Prenatal Diagnosis. American Journal of Human Genetics, 1998, 62, 768-775.	6.2	1,512
3	Rapid Clearance of Fetal DNA from Maternal Plasma. American Journal of Human Genetics, 1999, 64, 218-224.	6.2	1,006
4	Maternal Plasma DNA Sequencing Reveals the Genome-Wide Genetic and Mutational Profile of the Fetus. Science Translational Medicine, 2010, 2, 61ra91.	12.4	878
5	Noninvasive prenatal diagnosis of fetal chromosomal aneuploidy by massively parallel genomic sequencing of DNA in maternal plasma. Proceedings of the National Academy of Sciences of the United States of America, 2008, 105, 20458-20463.	7.1	809
6	Detection and Characterization of Placental MicroRNAs in Maternal Plasma. Clinical Chemistry, 2008, 54, 482-490.	3.2	775
7	Prenatal Diagnosis of Fetal RhD Status by Molecular Analysis of Maternal Plasma. New England Journal of Medicine, 1998, 339, 1734-1738.	27.0	676
8	Non-invasive prenatal assessment of trisomy 21 by multiplexed maternal plasma DNA sequencing: large scale validity study. BMJ: British Medical Journal, 2011, 342, c7401-c7401.	2.3	641
9	Plasma DNA tissue mapping by genome-wide methylation sequencing for noninvasive prenatal, cancer, and transplantation assessments. Proceedings of the National Academy of Sciences of the United States of America, 2015, 112, E5503-12.	7.1	579
10	Lengthening and shortening of plasma DNA in hepatocellular carcinoma patients. Proceedings of the National Academy of Sciences of the United States of America, 2015, 112, E1317-25.	7.1	543
11	Stability of Endogenous and Added RNA in Blood Specimens, Serum, and Plasma. Clinical Chemistry, 2002, 48, 1647-1653.	3.2	536
12	Analysis of Plasma Epstein–Barr Virus DNA to Screen for Nasopharyngeal Cancer. New England Journal of Medicine, 2017, 377, 513-522.	27.0	531
13	Effects of early corticosteroid treatment on plasma SARS-associated Coronavirus RNA concentrations in adult patients. Journal of Clinical Virology, 2004, 31, 304-309.	3.1	516
14	Size Distributions of Maternal and Fetal DNA in Maternal Plasma. Clinical Chemistry, 2004, 50, 88-92.	3.2	512
15	Predominant Hematopoietic Origin of Cell-free DNA in Plasma and Serum after Sex-mismatched Bone Marrow Transplantation. Clinical Chemistry, 2002, 48, 421-427.	3.2	483
16	Quantitative Abnormalities of Fetal DNA in Maternal Serum in Preeclampsia. Clinical Chemistry, 1999, 45, 184-188.	3.2	468
17	Microfluidics Digital PCR Reveals a Higher than Expected Fraction of Fetal DNA in Maternal Plasma. Clinical Chemistry, 2008, 54, 1664-1672.	3.2	396
18	Digital PCR for the molecular detection of fetal chromosomal aneuploidy. Proceedings of the National Academy of Sciences of the United States of America, 2007, 104, 13116-13121.	7.1	387

#	Article	IF	CITATIONS
19	Plasma Epstein-Barr Virus DNA and Residual Disease After Radiotherapy for Undifferentiated Nasopharyngeal Carcinoma. Journal of the National Cancer Institute, 2002, 94, 1614-1619.	6.3	384
20	Single-Molecule Detection of Epidermal Growth Factor Receptor Mutations in Plasma by Microfluidics Digital PCR in Non–Small Cell Lung Cancer Patients. Clinical Cancer Research, 2009, 15, 2076-2084.	7.0	371
21	mRNA of placental origin is readily detectable in maternal plasma. Proceedings of the National Academy of Sciences of the United States of America, 2003, 100, 4748-4753.	7.1	363
22	Noninvasive detection of cancer-associated genome-wide hypomethylation and copy number aberrations by plasma DNA bisulfite sequencing. Proceedings of the National Academy of Sciences of the United States of America, 2013, 110, 18761-18768.	7.1	363
23	Plasma placental RNA allelic ratio permits noninvasive prenatal chromosomal aneuploidy detection. Nature Medicine, 2007, 13, 218-223.	30.7	359
24	Plasma Epstein-Barr Viral Deoxyribonucleic Acid Quantitation Complements Tumor-Node-Metastasis Staging Prognostication in Nasopharyngeal Carcinoma. Journal of Clinical Oncology, 2006, 24, 5414-5418.	1.6	346
25	Effects of Blood-Processing Protocols on Fetal and Total DNA Quantification in Maternal Plasma. Clinical Chemistry, 2001, 47, 1607-1613.	3.2	330
26	Plasma DNA as a Prognostic Marker in Trauma Patients. Clinical Chemistry, 2000, 46, 319-323.	3.2	328
27	Antitumor Activity of Nivolumab in Recurrent and Metastatic Nasopharyngeal Carcinoma: An International, Multicenter Study of the Mayo Clinic Phase 2 Consortium (NCI-9742). Journal of Clinical Oncology, 2018, 36, 1412-1418.	1.6	324
28	Hypermethylated RASSF1A in Maternal Plasma: A Universal Fetal DNA Marker that Improves the Reliability of Noninvasive Prenatal Diagnosis. Clinical Chemistry, 2006, 52, 2211-2218.	3.2	319
29	Noninvasive prenatal diagnosis of monogenic diseases by digital size selection and relative mutation dosage on DNA in maternal plasma. Proceedings of the National Academy of Sciences of the United States of America, 2008, 105, 19920-19925.	7.1	310
30	Detection of the placental epigenetic signature of the maspin gene in maternal plasma. Proceedings of the National Academy of Sciences of the United States of America, 2005, 102, 14753-14758.	7.1	307
31	Noninvasive Prenatal Diagnosis of Congenital Adrenal Hyperplasia Using Cell-Free Fetal DNA in Maternal Plasma. Journal of Clinical Endocrinology and Metabolism, 2014, 99, E1022-E1030.	3.6	270
32	Prenatal exclusion of \hat{l}^2 thalassaemia major by examination of maternal plasma. Lancet, The, 2002, 360, 998-1000.	13.7	267
33	Presence of donor-specific DNA in plasma of kidney and liver-transplant recipients. Lancet, The, 1998, 351, 1329-1330.	13.7	266
34	Prognostic Use of Circulating Plasma Nucleic Acid Concentrations in Patients with Acute Stroke. Clinical Chemistry, 2003, 49, 562-569.	3.2	265
35	Epigenetics, fragmentomics, and topology of cell-free DNA in liquid biopsies. Science, 2021, 372, .	12.6	263
36	Presence of Fetal RNA in Maternal Plasma. Clinical Chemistry, 2000, 46, 1832-1834.	3.2	258

#	Article	IF	CITATIONS
37	Presence of Filterable and Nonfilterable mRNA in the Plasma of Cancer Patients and Healthy Individuals. Clinical Chemistry, 2002, 48, 1212-1217.	3.2	255
38	Maternal plasma fetal DNA as a marker for preterm labour. Lancet, The, 1998, 352, 1904-1905.	13.7	247
39	Noninvasive Prenatal Diagnosis of Fetal Trisomy 18 and Trisomy 13 by Maternal Plasma DNA Sequencing. PLoS ONE, 2011, 6, e21791.	2.5	243
40	Integrative single-cell and cell-free plasma RNA transcriptomics elucidates placental cellular dynamics. Proceedings of the National Academy of Sciences of the United States of America, 2017, 114, E7786-E7795.	7.1	242
41	The Long and Short of Circulating Cell-Free DNA and the Ins and Outs of Molecular Diagnostics. Trends in Genetics, 2016, 32, 360-371.	6.7	240
42	Detection of SARS Coronavirus RNA in the Cerebrospinal Fluid of a Patient with Severe Acute Respiratory Syndrome. Clinical Chemistry, 2003, 49, 2108-2109.	3.2	233
43	Size-based molecular diagnostics using plasma DNA for noninvasive prenatal testing. Proceedings of the National Academy of Sciences of the United States of America, 2014, 111, 8583-8588.	7.1	233
44	Noninvasive prenatal diagnosis of hemophilia by microfluidics digital PCR analysis of maternal plasma DNA. Blood, 2011, 117, 3684-3691.	1.4	232
45	Increased Maternal Plasma Fetal DNA Concentrations in Women Who Eventually Develop Preeclampsia Clinical Chemistry, 2001, 47, 137-139.	3.2	211
46	High-Resolution Profiling of Fetal DNA Clearance from Maternal Plasma by Massively Parallel Sequencing. Clinical Chemistry, 2013, 59, 1228-1237.	3.2	202
47	Early diagnosis of SARS Coronavirus infection by real time RT-PCR. Journal of Clinical Virology, 2003, 28, 233-238.	3.1	194
48	MS analysis of single-nucleotide differences in circulating nucleic acids: Application to noninvasive prenatal diagnosis. Proceedings of the National Academy of Sciences of the United States of America, 2004, 101, 10762-10767.	7.1	193
49	Predominant hematopoietic origin of cell-free DNA in plasma and serum after sex-mismatched bone marrow transplantation. Clinical Chemistry, 2002, 48, 421-7.	3.2	193
50	Differential DNA Methylation between Fetus and Mother as a Strategy for Detecting Fetal DNA in Maternal Plasma. Clinical Chemistry, 2002, 48, 35-41.	3.2	181
51	Quantitative Analysis of Circulating Mitochondrial DNA in Plasma. Clinical Chemistry, 2003, 49, 719-726.	3.2	181
52	Molecular characterization of circulating EBV DNA in the plasma of nasopharyngeal carcinoma and lymphoma patients. Cancer Research, 2003, 63, 2028-32.	0.9	181
53	Male microchimerism in healthy women and women with scleroderma: cells or circulating DNA? A quantitative answer. Blood, 2002, 100, 2845-2851.	1.4	179
54	Time Course of Early and Late Changes in Plasma DNA in Trauma Patients. Clinical Chemistry, 2003, 49, 1286-1291.	3.2	179

#	Article	IF	Citations
55	Prenatal diagnosis: progress through plasma nucleic acids. Nature Reviews Genetics, 2007, 8, 71-77.	16.3	176
56	Effects of Preanalytical Factors on the Molecular Size of Cell-Free DNA in Blood. Clinical Chemistry, 2005, 51, 781-784.	3.2	172
57	Tissue and cellular tropism of the coronavirus associated with severe acute respiratory syndrome: an in-situ hybridization study of fatal cases. Journal of Pathology, 2004, 202, 157-163.	4.5	168
58	The Concentration of Circulating Corticotropin-releasing Hormone mRNA in Maternal Plasma Is Increased in Preeclampsia. Clinical Chemistry, 2003, 49, 727-731.	3.2	161
59	Orientation-aware plasma cell-free DNA fragmentation analysis in open chromatin regions informs tissue of origin. Genome Research, 2019, 29, 418-427.	5 . 5	159
60	EDTA Is a Better Anticoagulant than Heparin or Citrate for Delayed Blood Processing for Plasma DNA Analysis. Clinical Chemistry, 2004, 50, 256-257.	3.2	158
61	Noninvasive Prenatal Diagnosis of Monogenic Diseases by Targeted Massively Parallel Sequencing of Maternal Plasma: Application to \hat{I}^2 -Thalassemia. Clinical Chemistry, 2012, 58, 1467-1475.	3.2	157
62	Noninvasive Prenatal Detection of Fetal Trisomy 18 by Epigenetic Allelic Ratio Analysis in Maternal Plasma: Theoretical and Empirical Considerations. Clinical Chemistry, 2006, 52, 2194-2202.	3.2	156
63	Diagnostic developments involving cell-free (circulating) nucleic acids. Clinica Chimica Acta, 2006, 363, 187-196.	1.1	155
64	Pretherapy quantitative measurement of circulating Epstein-Barr virus DNA is predictive of posttherapy distant failure in patients with early-stage nasopharyngeal carcinoma of undifferentiated type. Cancer, 2003, 98, 288-291.	4.1	154
65	Plasma DNA End-Motif Profiling as a Fragmentomic Marker in Cancer, Pregnancy, and Transplantation. Cancer Discovery, 2020, 10, 664-673.	9.4	152
66	Circulating nucleic acids in plasma/serum. Pathology, 2007, 39, 197-207.	0.6	151
67	An International Collaboration to Harmonize the Quantitative Plasma Epstein-Barr Virus DNA Assay for Future Biomarker-Guided Trials in Nasopharyngeal Carcinoma. Clinical Cancer Research, 2013, 19, 2208-2215.	7.0	149
68	Quantitative Analysis and Prognostic Implication of SARS Coronavirus RNA in the Plasma and Serum of Patients with Severe Acute Respiratory Syndrome. Clinical Chemistry, 2003, 49, 1976-1980.	3.2	148
69	Analysis of Plasma Epstein-Barr Virus DNA in Nasopharyngeal Cancer After Chemoradiation to Identify High-Risk Patients for Adjuvant Chemotherapy: A Randomized Controlled Trial. Journal of Clinical Oncology, 2018, 36, 3091-3100.	1.6	147
70	Host-response biomarkers for diagnosis of late-onset septicemia and necrotizing enterocolitis in preterm infants. Journal of Clinical Investigation, 2010, 120, 2989-3000.	8.2	146
71	Noninvasive Prenatal Exclusion of Congenital Adrenal Hyperplasia by Maternal Plasma Analysis: A Feasibility Study. Clinical Chemistry, 2002, 48, 778-780.	3.2	145
72	Second generation noninvasive fetal genome analysis reveals de novo mutations, single-base parental inheritance, and preferred DNA ends. Proceedings of the National Academy of Sciences of the United States of America, 2016, 113, E8159-E8168.	7.1	142

#	Article	IF	CITATIONS
73	Quantitative Analysis of Circulating Methylated DNA as a Biomarker for Hepatocellular Carcinoma. Clinical Chemistry, 2008, 54, 1528-1536.	3.2	141
74	Preferred end coordinates and somatic variants as signatures of circulating tumor DNA associated with hepatocellular carcinoma. Proceedings of the National Academy of Sciences of the United States of America, 2018, 115, E10925-E10933.	7.1	140
75	Early detection of nasopharyngeal carcinoma by plasma Epsteinâ€Barr virus DNA analysis in a surveillance program. Cancer, 2013, 119, 1838-1844.	4.1	137
76	The 3a protein of severe acute respiratory syndrome-associated coronavirus induces apoptosis in Vero E6 cells. Journal of General Virology, 2005, 86, 1921-1930.	2.9	135
77	Plasma Nucleic Acids in the Diagnosis and Management of Malignant Disease. Clinical Chemistry, 2002, 48, 1186-1193.	3.2	134
78	<i>Dnase113</i> deletion causes aberrations in length and end-motif frequencies in plasma DNA. Proceedings of the National Academy of Sciences of the United States of America, 2019, 116, 641-649.	7.1	134
79	Noninvasive Prenatal Methylomic Analysis by Genomewide Bisulfite Sequencing of Maternal Plasma DNA. Clinical Chemistry, 2013, 59, 1583-1594.	3.2	131
80	Hypermethylation of RASSF1A in Human and Rhesus Placentas. American Journal of Pathology, 2007, 170, 941-950.	3.8	128
81	The Biology of Cell-free DNA Fragmentation and the Roles of DNASE1, DNASE1L3, and DFFB. American Journal of Human Genetics, 2020, 106, 202-214.	6.2	127
82	Phase II Study of Neoadjuvant Carboplatin and Paclitaxel Followed by Radiotherapy and Concurrent Cisplatin in Patients With Locoregionally Advanced Nasopharyngeal Carcinoma: Therapeutic Monitoring With Plasma Epstein-Barr Virus DNA. Journal of Clinical Oncology, 2004, 22, 3053-3060.	1.6	125
83	Maternal Plasma DNA Analysis with Massively Parallel Sequencing by Ligation for Noninvasive Prenatal Diagnosis of Trisomy 21. Clinical Chemistry, 2010, 56, 459-463.	3.2	125
84	Systematic Search for Placental DNA-Methylation Markers on Chromosome 21: Toward a Maternal Plasma-Based Epigenetic Test for Fetal Trisomy 21. Clinical Chemistry, 2008, 54, 500-511.	3.2	123
85	Fetal DNA Clearance from Maternal Plasma Is Impaired in Preeclampsia. Clinical Chemistry, 2002, 48, 2141-2146.	3.2	118
86	Noninvasive Prenatal Detection of Trisomy 21 by an Epigenetic–Genetic Chromosome-Dosage Approach. Clinical Chemistry, 2010, 56, 90-98.	3.2	115
87	Cell-free nucleic acids in plasma, serum and urine: a new tool in molecular diagnosis. Annals of Clinical Biochemistry, 2003, 40, 122-130.	1.6	114
88	Sequencing-based counting and size profiling of plasma Epstein–Barr virus DNA enhance population screening of nasopharyngeal carcinoma. Proceedings of the National Academy of Sciences of the United States of America, 2018, 115, E5115-E5124.	7.1	114
89	Cell-Free DNA in Serum and Plasma: Comparison of ELISA and Quantitative PCR. Clinical Chemistry, 2005, 51, 1544-1546.	3.2	111
90	Targeted Massively Parallel Sequencing of Maternal Plasma DNA Permits Efficient and Unbiased Detection of Fetal Alleles. Clinical Chemistry, 2011, 57, 92-101.	3.2	111

#	Article	IF	CITATIONS
91	Size-tagged preferred ends in maternal plasma DNA shed light on the production mechanism and show utility in noninvasive prenatal testing. Proceedings of the National Academy of Sciences of the United States of America, 2018, 115, E5106-E5114.	7.1	107
92	Identification and characterization of extrachromosomal circular DNA in maternal plasma. Proceedings of the National Academy of Sciences of the United States of America, 2020, 117, 1658-1665.	7.1	106
93	Circulating biomarkers in the diagnosis and management of hepatocellular carcinoma. Nature Reviews Gastroenterology and Hepatology, 2022, 19, 670-681.	17.8	106
94	Improved Accuracy of Detection of Nasopharyngeal Carcinoma by Combined Application of Circulating Epstein–Barr Virus DNA and Anti-Epstein–Barr Viral Capsid Antigen IgA Antibody. Clinical Chemistry, 2004, 50, 339-345.	3.2	105
95	Quantification of Plasma \hat{I}^2 -Catenin mRNA in Colorectal Cancer and Adenoma Patients. Clinical Cancer Research, 2004, 10, 1613-1617.	7.0	105
96	Relationship between pretreatment level of plasma Epstein-Barr virus DNA, tumor burden, and metabolic activity in advanced nasopharyngeal carcinoma. International Journal of Radiation Oncology Biology Physics, 2006, 66, 714-720.	0.8	105
97	Plasma DNA aberrations in systemic lupus erythematosus revealed by genomic and methylomic sequencing. Proceedings of the National Academy of Sciences of the United States of America, 2014, 111, E5302-11.	7.1	105
98	Presence of Donor- and Recipient-derived DNA in Cell-free Urine Samples of Renal Transplantation Recipients: Urinary DNA Chimerism. Clinical Chemistry, 1999, 45, 1741-1746.	3.2	104
99	Nonhematopoietically Derived DNA Is Shorter than Hematopoietically Derived DNA in Plasma: A Transplantation Model. Clinical Chemistry, 2012, 58, 549-558.	3.2	103
100	Quantitative analysis of circulating cell-free Epstein-Barr virus (EBV) DNA levels in patients with EBV-associated lymphoid malignancies. British Journal of Haematology, 2000, 111, 239-246.	2.5	102
101	Prenatal Diagnosis Innovation: Genome Sequencing of Maternal Plasma. Annual Review of Medicine, 2016, 67, 419-432.	12.2	97
102	Plasma Mitochondrial DNA Concentrations after Trauma. Clinical Chemistry, 2004, 50, 213-216.	3.2	95
103	Non-invasive prenatal diagnosis by single molecule counting technologies. Trends in Genetics, 2009, 25, 324-331.	6.7	95
104	Maternal Plasma Fetal DNA Fractions in Pregnancies with Low and High Risks for Fetal Chromosomal Aneuploidies. PLoS ONE, 2014, 9, e88484.	2.5	92
105	Fetal Cell-free Plasma DNA Concentrations in Maternal Blood Are Stable 24 Hours after Collection: Analysis of First- and Third-Trimester Samples. Clinical Chemistry, 2003, 49, 195-198.	3.2	91
106	Universal Haplotype-Based Noninvasive Prenatal Testing for Single Gene Diseases. Clinical Chemistry, 2017, 63, 513-524.	3.2	89
107	High Resolution Size Analysis of Fetal DNA in the Urine of Pregnant Women by Paired-End Massively Parallel Sequencing. PLoS ONE, 2012, 7, e48319.	2.5	86
108	Serum Proteomic Fingerprints of Adult Patients with Severe Acute Respiratory Syndrome. Clinical Chemistry, 2006, 52, 421-429.	3.2	83

#	Article	IF	Citations
109	A phase II study of patients with metastatic or locoregionally recurrent nasopharyngeal carcinoma and evaluation of plasma Epstein–Barr virus DNA as a biomarker of efficacy. Cancer Chemotherapy and Pharmacology, 2008, 62, 59-64.	2.3	82
110	Maternal Plasma RNA Sequencing for Genome-Wide Transcriptomic Profiling and Identification of Pregnancy-Associated Transcripts. Clinical Chemistry, 2014, 60, 954-962.	3.2	80
111	ACE2 Gene Polymorphisms Do Not Affect Outcome of Severe Acute Respiratory Syndrome. Clinical Chemistry, 2004, 50, 1683-1686.	3.2	76
112	Noninvasive twin zygosity assessment and aneuploidy detection by maternal plasma DNA sequencing. Prenatal Diagnosis, 2013, 33, 675-681.	2.3	75
113	Noninvasive Prenatal Molecular Karyotyping from Maternal Plasma. PLoS ONE, 2013, 8, e60968.	2.5	70
114	Origin of Plasma Cell-free DNA after Solid Organ Transplantation. Clinical Chemistry, 2003, 49, 495-496.	3.2	69
115	Coronavirus Genomic-Sequence Variations and the Epidemiology of the Severe Acute Respiratory Syndrome. New England Journal of Medicine, 2003, 349, 187-188.	27.0	68
116	Persistent Aberrations in Circulating DNA Integrity after Radiotherapy Are Associated with Poor Prognosis in Nasopharyngeal Carcinoma Patients. Clinical Cancer Research, 2008, 14, 4141-4145.	7.0	68
117	Non-invasive prenatal diagnosis by fetal nucleic acid analysis in maternal plasma: the coming of age. Seminars in Fetal and Neonatal Medicine, 2011, 16, 88-93.	2.3	67
118	Serial Analysis of the Plasma Concentration of SARS Coronavirus RNA in Pediatric Patients with Severe Acute Respiratory Syndrome. Clinical Chemistry, 2003, 49, 2085-2088.	3.2	66
119	Quantitative aberrations of hypermethylated <i>RASSF1A</i> gene sequences in maternal plasma in preâ€eclampsia. Prenatal Diagnosis, 2007, 27, 1212-1218.	2.3	66
120	The Nexus of cfDNA and Nuclease Biology. Trends in Genetics, 2021, 37, 758-770.	6.7	66
121	<i>FetalQuant</i> : deducing fractional fetal DNA concentration from massively parallel sequencing of DNA in maternal plasma. Bioinformatics, 2012, 28, 2883-2890.	4.1	65
122	Genome-wide detection of cytosine methylation by single molecule real-time sequencing. Proceedings of the National Academy of Sciences of the United States of America, 2021, 118, .	7.1	65
123	Circulating Nucleic Acids in Plasma and Serum: An Overview. Annals of the New York Academy of Sciences, 2001, 945, 1-7.	3.8	64
124	Noninvasive Prenatal Determination of Twin Zygosity by Maternal Plasma DNA Analysis. Clinical Chemistry, 2013, 59, 427-435.	3.2	64
125	Noninvasive Prenatal Diagnosis of Fetal Chromosomal Aneuploidies by Maternal Plasma Nucleic Acid Analysis. Clinical Chemistry, 2008, 54, 461-466.	3.2	63
126	Genomic Analysis of Fetal Nucleic Acids in Maternal Blood. Annual Review of Genomics and Human Genetics, 2012, 13, 285-306.	6.2	63

#	Article	IF	Citations
127	DNA of Erythroid Origin Is Present in Human Plasma and Informs the Types of Anemia. Clinical Chemistry, 2017, 63, 1614-1623.	3.2	63
128	Fetomaternal Cellular and Plasma DNA Trafficking. Annals of the New York Academy of Sciences, 2001, 945, 119-131.	3.8	62
129	Prenatal detection of fetal Down's syndrome from maternal plasma. Lancet, The, 2000, 356, 1819-1820.	13.7	61
130	Detection and characterization of jagged ends of double-stranded DNA in plasma. Genome Research, 2020, 30, 1144-1153.	5.5	61
131	Circulating Corticotropin-Releasing Hormone mRNA in Maternal Plasma: Relationship with Gestational Age and Severity of Preeclampsia. Clinical Chemistry, 2004, 50, 1851-1854.	3.2	60
132	Quantitative Analysis of the Transrenal Excretion of Circulating EBV DNA in Nasopharyngeal Carcinoma Patients. Clinical Cancer Research, 2008, 14, 4809-4813.	7.0	60
133	Genomewide bisulfite sequencing reveals the origin and time-dependent fragmentation of urinary cfDNA. Clinical Biochemistry, 2017, 50, 496-501.	1.9	60
134	Liver- and Colon-Specific DNA Methylation Markers in Plasma for Investigation of Colorectal Cancers with or without Liver Metastases. Clinical Chemistry, 2018, 64, 1239-1249.	3.2	60
135	Circulating Placental RNA in Maternal Plasma Is Associated with a Preponderance of 5′ mRNA Fragments: Implications for Noninvasive Prenatal Diagnosis and Monitoring. Clinical Chemistry, 2005, 51, 1786-1795.	3.2	59
136	Fifty Years of Molecular (DNA/RNA) Diagnostics. Clinical Chemistry, 2005, 51, 661-671.	3.2	58
137	Noninvasive Prenatal Screening for Genetic Diseases Using Massively Parallel Sequencing of Maternal Plasma DNA. Cold Spring Harbor Perspectives in Medicine, 2015, 5, a023085.	6.2	58
138	Cell-free DNA in maternal plasma and serum: A comparison of quantity, quality and tissue origin using genomic and epigenomic approaches. Clinical Biochemistry, 2016, 49, 1379-1386.	1.9	58
139	Noninvasive Prenatal Diagnosis of Fetal Trisomy 21 by Allelic Ratio Analysis Using Targeted Massively Parallel Sequencing of Maternal Plasma DNA. PLoS ONE, 2012, 7, e38154.	2.5	58
140	Quantitative Analysis of Epsteinâ€Barr Virus DNA in Plasma and Serum. Annals of the New York Academy of Sciences, 2001, 945, 68-72.	3.8	57
141	Synergy of Total PLAC4 RNA Concentration and Measurement of the RNA Single-Nucleotide Polymorphism Allelic Ratio for the Noninvasive Prenatal Detection of Trisomy 21. Clinical Chemistry, 2010, 56, 73-81.	3.2	57
142	Differential DNA methylation between fetus and mother as a strategy for detecting fetal DNA in maternal plasma. Clinical Chemistry, 2002, 48, 35-41.	3.2	56
143	Methy-Pipe: An Integrated Bioinformatics Pipeline for Whole Genome Bisulfite Sequencing Data Analysis. PLoS ONE, 2014, 9, e100360.	2.5	54
144	Plasma Epstein–Barr virus DNA as an archetypal circulating tumour DNA marker. Journal of Pathology, 2019, 247, 641-649.	4.5	53

#	Article	IF	Citations
145	Fetal RhD genotyping from maternal plasma. Annals of Medicine, 1999, 31, 308-312.	3.8	52
146	Lack of Dramatic Enrichment of Fetal DNA in Maternal Plasma by Formaldehyde Treatment. Clinical Chemistry, 2005, 51, 655-658.	3.2	52
147	Methylation analysis of plasma DNA informs etiologies of Epstein-Barr virus-associated diseases. Nature Communications, 2019, 10, 3256.	12.8	52
148	Noninvasive detection of F8 int22h-related inversions and sequence variants in maternal plasma of hemophilia carriers. Blood, 2017, 130, 340-347.	1.4	51
149	Recent Advances in Fetal Nucleic Acids in Maternal Plasma. Journal of Histochemistry and Cytochemistry, 2005, 53, 293-296.	2.5	50
150	Genome-wide expression analysis using microarray identified complex signaling pathways modulated by hypoxia in nasopharyngeal carcinoma. Cancer Letters, 2007, 253, 74-88.	7.2	50
151	Non-invasive prenatal testing using massively parallel sequencing of maternal plasma DNA: from molecular karyotyping to fetal whole-genome sequencing. Reproductive BioMedicine Online, 2013, 27, 593-598.	2.4	48
152	Investigation into the Origin and Tumoral Mass Correlation of Plasma Epstein–Barr Virus DNA in Nasopharyngeal Carcinoma. Clinical Chemistry, 2005, 51, 2192-2195.	3.2	46
153	Time Profile of Appearance and Disappearance of Circulating Placenta-Derived mRNA in Maternal Plasma. Clinical Chemistry, 2006, 52, 313-316.	3.2	46
154	Plasma \hat{l}^2 -globin DNA as a prognostic marker in chest pain patients. Clinica Chimica Acta, 2006, 368, 110-113.	1.1	45
155	Comparison of plasma β-globin DNA and S-100 protein concentrations in acute stroke. Clinica Chimica Acta, 2007, 376, 190-196.	1.1	45
156	Clinical applications of maternal plasma fetal DNA analysis: translating the fruits of 15 years of research. Clinical Chemistry and Laboratory Medicine, 2013, 51, 197-204.	2.3	45
157	Evaluation of Human Chorionic Gonadotropin β-Subunit mRNA Concentrations in Maternal Serum in Aneuploid Pregnancies: A Feasibility Study. Clinical Chemistry, 2004, 50, 1055-1057.	3.2	44
158	Noninvasive Prenatal Testing by Nanopore Sequencing of Maternal Plasma DNA: Feasibility Assessment. Clinical Chemistry, 2015, 61, 1305-1306.	3.2	44
159	Single-molecule sequencing reveals a large population of long cell-free DNA molecules in maternal plasma. Proceedings of the National Academy of Sciences of the United States of America, 2021, 118, .	7.1	43
160	Cell-Free DNA Fragmentomics in Liquid Biopsy. Diagnostics, 2022, 12, 978.	2.6	43
161	Circulating DNA in Plasma and Serum: Biology, Preanalytical Issues and Diagnostic Applications. Clinical Chemistry and Laboratory Medicine, 2002, 40, 962-8.	2.3	41
162	Absence of association between angiotensin converting enzyme polymorphism and development of adult respiratory distress syndrome in patients with severe acute respiratory syndrome: a case control study. BMC Infectious Diseases, 2005, 5, 26.	2.9	41

#	Article	IF	CITATIONS
163	Epigenetic Tumor Markers in Plasma and Serum. Annals of the New York Academy of Sciences, 2001, 945, 36-50.	3.8	41
164	Tracing SARS-Coronavirus Variant with Large Genomic Deletion. Emerging Infectious Diseases, 2005, 11, 168-170.	4.3	40
165	Detection of <i>Plasmodium falciparum</i> DNA in Plasma. Annals of the New York Academy of Sciences, 2001, 945, 234-238.	3.8	40
166	Detection of Trisomy 21 by Quantitative Mass Spectrometric Analysis of Single-Nucleotide Polymorphisms. Clinical Chemistry, 2005, 51, 2358-2362.	3.2	37
167	Plasma DNA Profile Associated with DNASE1L3 Gene Mutations: Clinical Observations, Relationships to Nuclease Substrate Preference, and InâVivo Correction. American Journal of Human Genetics, 2020, 107, 882-894.	6.2	37
168	Serologic Antienzyme Rate of Epstein-Barr Virus DNase-Specific Neutralizing Antibody Segregates TNM Classification in Nasopharyngeal Carcinoma. Journal of Clinical Oncology, 2010, 28, 5202-5209.	1.6	35
169	DNase1 Does Not Appear to Play a Major Role in the Fragmentation of Plasma DNA in a Knockout Mouse Model. Clinical Chemistry, 2018, 64, 406-408.	3.2	34
170	Noninvasive Detection of Bladder Cancer by Shallow-Depth Genome-Wide Bisulfite Sequencing of Urinary Cell-Free DNA for Methylation and Copy Number Profiling. Clinical Chemistry, 2019, 65, 927-936.	3.2	34
171	Epigenetic-Genetic Chromosome Dosage Approach for Fetal Trisomy 21 Detection Using an Autosomal Genetic Reference Marker. PLoS ONE, 2010, 5, e15244.	2.5	33
172	Non-invasive prenatal diagnosis by massively parallel sequencing of maternal plasma DNA. Open Biology, 2012, 2, 120086.	3.6	33
173	The Biology and Diagnostic Applications of Fetal DNA and RNA in Maternal Plasma. Current Topics in Developmental Biology, 2004, 61, 81-111.	2.2	32
174	Nonâ€invasive prenatal detection of fetal trisomy 18 by RNAâ€"SNP allelic ratio analysis using maternal plasma <i>SERPINB2</i> mRNA: a feasibility study. Prenatal Diagnosis, 2009, 29, 1031-1037.	2.3	32
175	Serial Analysis of Plasma Proteomic Signatures in Pediatric Patients with Severe Acute Respiratory Syndrome and Correlation with Viral Load. Clinical Chemistry, 2004, 50, 1452-1455.	3.2	31
176	Synthetic Peptide Studies on the Severe Acute Respiratory Syndrome (SARS) Coronavirus Spike Glycoprotein: Perspective for SARS Vaccine Development. Clinical Chemistry, 2004, 50, 1036-1042.	3.2	31
177	Detection of Mammaglobin mRNA in the Plasma of Breast Cancer Patients. Annals of the New York Academy of Sciences, 2001, 945, 192-194.	3.8	31
178	Fetal DNA in Maternal Plasma. Annals of the New York Academy of Sciences, 2000, 906, 141-147.	3.8	31
179	Next-Generation Sequencing of Plasma/Serum DNA: An Emerging Research and Molecular Diagnostic Tool. Clinical Chemistry, 2009, 55, 607-608.	3.2	31
180	FetalQuantSD: accurate quantification of fetal DNA fraction by shallow-depth sequencing of maternal plasma DNA. Npj Genomic Medicine, 2016, 1, 16013.	3.8	31

#	Article	IF	CITATIONS
181	Liver-derived cell-free nucleic acids in plasma: Biology and applications in liquid biopsies. Journal of Hepatology, 2019, 71, 409-421.	3.7	31
182	Placenta-Derived Fetal Specific mRNA Is More Readily Detectable in Maternal Plasma than in Whole Blood. PLoS ONE, 2009, 4, e5858.	2.5	31
183	Serial Analysis of Fetal DNA Concentrations in Maternal Plasma in Late Pregnancy. Clinical Chemistry, 2003, 49, 678-680.	3.2	30
184	A strategy for identifying circulating placental RNA markers for fetal growth assessment. Prenatal Diagnosis, 2009, 29, 495-504.	2.3	30
185	Single-cell transcriptomics reveal that PD-1 mediates immune tolerance by regulating proliferation of regulatory T cells. Genome Medicine, 2018, 10, 71.	8.2	30
186	Application of fetal DNA in maternal plasma for noninvasive prenatal diagnosis. Expert Review of Molecular Diagnostics, 2002, 2, 32-40.	3.1	29
187	Nasopharyngeal carcinoma in situ (NPCIS)?pathologic and clinical perspectives. Head and Neck, 2002, 24, 989-995.	2.0	29
188	Quantitative Analysis of Pleural Fluid Cell-free DNA as a Tool for the Classification of Pleural Effusions. Clinical Chemistry, 2003, 49, 740-745.	3.2	29
189	Cell-free DNA and RNA in plasma as new tools for molecular diagnostics. Expert Review of Molecular Diagnostics, 2003, 3, 785-797.	3.1	28
190	Tumorâ€Derived Epigenetic Changes in the Plasma and Serum of Liver Cancer Patients: Implications for Cancer Detection and Monitoring. Annals of the New York Academy of Sciences, 2000, 906, 102-105.	3.8	28
191	Noninvasive fetal genomic, methylomic, and transcriptomic analyses using maternal plasma and clinical implications. Trends in Molecular Medicine, 2015, 21, 98-108.	6.7	28
192	The Biology and Diagnostic Applications of Plasma RNA. Annals of the New York Academy of Sciences, 2004, 1022, 135-139.	3.8	27
193	Reduced Plasma RNA Integrity in Nasopharyngeal Carcinoma Patients. Clinical Cancer Research, 2006, 12, 2512-2516.	7.0	27
194	Detection of Restriction Enzyme–Digested Target DNA by PCR Amplification Using a Stem-Loop Primer: Application to the Detection of Hypomethylated Fetal DNA in Maternal Plasma. Clinical Chemistry, 2007, 53, 1906-1914.	3.2	27
195	Presence of Donor-Derived DNA and Cells in the Urine of Sex-Mismatched Hematopoietic Stem Cell Transplant Recipients: Implication for the Transrenal Hypothesis. Clinical Chemistry, 2009, 55, 715-722.	3.2	27
196	Noninvasive prenatal diagnosis empowered by highâ€throughput sequencing. Prenatal Diagnosis, 2012, 32, 401-406.	2.3	27
197	Epigenetic approaches for the detection of fetal DNA in maternal plasma. Chimerism, 2010, 1, 30-35.	0.7	26
198	Racing Towards the Development of Diagnostics for a Novel Coronavirus (2019-nCoV). Clinical Chemistry, 2020, 66, 503-504.	3.2	26

#	Article	IF	Citations
199	Characteristics of Fetal Extrachromosomal Circular DNA in Maternal Plasma: Methylation Status and Clearance. Clinical Chemistry, 2021, 67, 788-796.	3.2	26
200	Molecular Analysis of Circulating RNA in Plasma. , 2006, 336, 123-134.		25
201	Mass Spectrometric Detection of an SNP Panel as an Internal Positive Control for Fetal DNA Analysis in Maternal Plasma. Clinical Chemistry, 2007, 53, 141-142.	3.2	25
202	Systematic Identification of Placental Epigenetic Signatures for the Noninvasive Prenatal Detection of Edwards Syndrome. PLoS ONE, 2010, 5, e15069.	2.5	25
203	Noninvasive Prenatal Diagnosis of a Case of Down Syndrome due to Robertsonian Translocation by Massively Parallel Sequencing of Maternal Plasma DNA. Clinical Chemistry, 2011, 57, 917-919.	3.2	25
204	Setting Up a Polymerase Chain Reaction Laboratory. , 2006, 336, 11-18.		24
205	Single-Stranded DNA Library Preparation Preferentially Enriches Short Maternal DNA in Maternal Plasma. Clinical Chemistry, 2017, 63, 1031-1037.	3.2	24
206	Prospective evaluation of plasma Epstein–Barr virus DNA clearance and fluorodeoxyglucose positron emission scan in assessing early response to chemotherapy in patients with advanced or recurrent nasopharyngeal carcinoma. British Journal of Cancer, 2018, 118, 1051-1055.	6.4	24
207	Jagged Ends of Urinary Cell-Free DNA: Characterization and Feasibility Assessment in Bladder Cancer Detection. Clinical Chemistry, 2021, 67, 621-630.	3.2	24
208	Derivation of a Prediction Rule for Posttraumatic Organ Failure Using Plasma DNA and Other Variables. Annals of the New York Academy of Sciences, 2001, 945, 211-220.	3.8	23
209	Noninvasive prenatal diagnosis in 2020. Prenatal Diagnosis, 2010, 30, 702-703.	2.3	23
210	Proteomic analysis reveals platelet factor 4 and beta-thromboglobulin as prognostic markers in severe acute respiratory syndrome. Electrophoresis, 2012, 33, 1894-1900.	2.4	23
211	The ins and outs of fetal DNA in maternal plasma. Lancet, The, 2003, 361, 193-194.	13.7	22
212	Single-Molecule Sequencing Enables Long Cell-Free DNA Detection and Direct Methylation Analysis for Cancer Patients. Clinical Chemistry, 2022, 68, 1151-1163.	3.2	22
213	Molecular Epidemiology of SARS â€" From Amoy Gardens to Taiwan. New England Journal of Medicine, 2003, 349, 1875-1876.	27.0	21
214	Mass Spectrometry–Based Detection of Hemoglobin E Mutation by Allele-Specific Base Extension Reaction. Clinical Chemistry, 2007, 53, 2205-2209.	3.2	21
215	Noninvasive fetal <i>RHD</i> genotyping by microfluidics digital PCR using maternal plasma from two alloimmunized women with the variant <i>RHD</i> (IVS3+1G>A) allele. Prenatal Diagnosis, 2013, 33, 1214-1216.	2.3	21
216	Molecular Diagnostics: A Revolution in Progress. Clinical Chemistry, 2015, 61, 1-3.	3.2	21

#	Article	IF	CITATIONS
217	Plasma epigenetic markers for cancer detection and prenatal diagnosis. Frontiers in Bioscience - Landmark, 2006, 11, 2647.	3.0	20
218	Aberrant Concentrations of Liver-Derived Plasma Albumin mRNA in Liver Pathologies. Clinical Chemistry, 2010, 56, 82-89.	3.2	20
219	Early Detection of Cancer: Evaluation of MR Imaging Grading Systems in Patients with Suspected Nasopharyngeal Carcinoma. American Journal of Neuroradiology, 2020, 41, 515-521.	2.4	20
220	The prognostic significance of tumor vascular invasion and its association with plasma Epstein-Barr virus DNA, tumor volume and metabolic activity in locoregionally advanced nasopharyngeal carcinoma. Oral Oncology, 2008, 44, 1067-1072.	1.5	19
221	Topologic Analysis of Plasma Mitochondrial DNA Reveals the Coexistence of Both Linear and Circular Molecules. Clinical Chemistry, 2019, 65, 1161-1170.	3.2	19
222	Applications of genetic-epigenetic tissue mapping for plasma DNA in prenatal testing, transplantation and oncology. ELife, $2021,10,10$	6.0	19
223	Noninvasive Approaches to Prenatal Diagnosis of Hemoglobinopathies Using Fetal DNA in Maternal Plasma. Hematology/Oncology Clinics of North America, 2010, 24, 1179-1186.	2.2	18
224	Recent advances in the analysis of fetal nucleic acids in maternal plasma. Current Opinion in Hematology, 2012, 19, 462-468.	2.5	18
225	A New Era in Prenatal Diagnosis: The Use of Cell-Free Fetal DNA in Maternal Circulation for Detection of Chromosomal Aneuploidies. Clinical Chemistry, 2013, 59, 1151-1159.	3.2	18
226	Ambient Temperature and Screening for Nasopharyngeal Cancer. New England Journal of Medicine, 2018, 378, 962-963.	27.0	18
227	Cell-Free DNA Fragmentomics: The New "Omics―on the Block. Clinical Chemistry, 2020, 66, 1480-1484.	3.2	18
228	Effects of Filtration on Glyceraldehyde-3-Phosphate Dehydrogenase mRNA in the Plasma of Trauma Patients and Healthy Individuals. Clinical Chemistry, 2004, 50, 206-208.	3.2	17
229	Quantitative Analysis of Cell-Free Epstein-Barr Virus DNA in Plasma of Patients with Nonnasopharyngeal Head and Neck Carcinomas. Clinical Cancer Research, 2004, 10, 1726-1732.	7.0	17
230	Placental RNA in Maternal Plasma: Toward Noninvasive Fetal Gene Expression Profiling. Annals of the New York Academy of Sciences, 2006, 1075, 96-102.	3.8	17
231	Transplantation Monitoring by Plasma DNA Sequencing. Clinical Chemistry, 2011, 57, 941-942.	3.2	17
232	COFFEE: controlâ€free noninvasive fetal chromosomal examination using maternal plasma DNA. Prenatal Diagnosis, 2017, 37, 336-340.	2.3	17
233	Fetal DNA in Maternal Plasma: Progress through Epigenetics. Annals of the New York Academy of Sciences, 2006, 1075, 74-80.	3.8	16
234	Cytokine Profile in Fatal Human Immunodeficiency Virus–Tuberculosis–Epstein-Barr Virus–Associated Hemophagocytic Syndrome. Archives of Internal Medicine, 2007, 167, 1901.	3.8	16

#	Article	IF	CITATIONS
235	Pregnancy-Associated MicroRNAs in Maternal Plasma: A Channel for Fetal–Maternal Communication?. Clinical Chemistry, 2010, 56, 1656-1657.	3.2	16
236	Combined Count- and Size-Based Analysis of Maternal Plasma DNA for Noninvasive Prenatal Detection of Fetal Subchromosomal Aberrations Facilitates Elucidation of the Fetal and/or Maternal Origin of the Aberrations. Clinical Chemistry, 2017, 63, 495-502.	3.2	16
237	Noninvasive reconstruction of placental methylome from maternal plasma DNA: Potential for prenatal testing and monitoring. Prenatal Diagnosis, 2018, 38, 196-203.	2.3	16
238	Cellâ€free fetal DNA coming in all sizes and shapes. Prenatal Diagnosis, 2021, 41, 1193-1201.	2.3	16
239	Distribution of Cell-Free and Cell-Associated Epstein–Barr Virus (EBV) DNA in the Blood of Patients with Nasopharyngeal Carcinoma and EBV-Associated Lymphoma. Clinical Chemistry, 2004, 50, 1842-1845.	3.2	15
240	Epigenetic Analysis of RASSF1A Gene in Cell-Free DNA in Amniotic Fluid. Clinical Chemistry, 2007, 53, 796-798.	3.2	15
241	Fetal Nucleic Acids in Maternal Plasma. Annals of the New York Academy of Sciences, 2008, 1137, 140-143.	3.8	15
242	Circulating Nucleic Acids in Plasma/Serum III and Serum Proteomics Recent Developments in Fetal DNA in Maternal Plasma. Annals of the New York Academy of Sciences, 2004, 1022, 100-104.	3.8	14
243	Serum Amyloid A Is Not Useful in the Diagnosis of Severe Acute Respiratory Syndrome. Clinical Chemistry, 2006, 52, 1202-1204.	3.2	14
244	SFRS7-Mediated Splicing of Tau Exon 10 Is Directly Regulated by STOX1A in Glial Cells. PLoS ONE, 2011, 6, e21994.	2.5	14
245	Prenatal assessment of fetal chromosomal and genetic disorders through maternal plasma DNA analysis. Pathology, 2012, 44, 69-72.	0.6	14
246	Noninvasive Prenatal Diagnosis of Congenital Adrenal Hyperplasia. Endocrine Development, 2016, 30, 37-41.	1.3	14
247	Gestational Age Assessment by Methylation and Size Profiling of Maternal Plasma DNA: A Feasibility Study. Clinical Chemistry, 2017, 63, 606-608.	3.2	14
248	Non-invasive prenatal diagnosis: on the horizon?. Pharmacogenomics, 2003, 4, 191-200.	1.3	13
249	Reply to "STOX1 is not imprinted and is not likely to be involved in preeclampsia― Nature Genetics, 2007, 39, 280-281.	21.4	13
250	Technical concerns about immunoprecipitation of methylated fetal DNA for noninvasive trisomy 21 diagnosis. Nature Medicine, 2012, 18, 1327-1328.	30.7	13
251	Dynamic Changes of Post-Radiotherapy Plasma Epstein–Barr Virus DNA in a Randomized Trial of Adjuvant Chemotherapy Versus Observation in Nasopharyngeal Cancer. Clinical Cancer Research, 2021, 27, 2827-2836.	7.0	13
252	A multicenter randomized controlled trial (RCT) of adjuvant chemotherapy (CT) in nasopharyngeal carcinoma (NPC) with residual plasma EBV DNA (EBV DNA) following primary radiotherapy (RT) or chemoradiation (CRT) Journal of Clinical Oncology, 2017, 35, 6002-6002.	1.6	13

#	Article	IF	CITATIONS
253	Genomic Sequencing of a SARS Coronavirus Isolate That Predated the Metropole Hotel Case Cluster in Hong Kong. Clinical Chemistry, 2004, 50, 231-233.	3.2	12
254	Comparison of Protocols for Extracting Circulating DNA and RNA from Maternal Plasma. Clinical Chemistry, 2005, 51, 2209-2210.	3.2	12
255	Circulating Fetal RNA in Maternal Plasma. Annals of the New York Academy of Sciences, 2001, 945, 207-210.	3.8	12
256	A Microarray Approach for Systematic Identification of Placental-Derived RNA Markers in Maternal Plasma. Methods in Molecular Biology, 2008, 444, 275-289.	0.9	12
257	Noninvasive Prenatal Diagnosis: From Dream to Reality. Clinical Chemistry, 2015, 61, 32-37.	3.2	12
258	Effects of nucleases on cell-free extrachromosomal circular DNA. JCI Insight, 2022, 7, .	5.0	12
259	MALDI-TOF Mass Spectrometry for Quantitative, Specific, and Sensitive Analysis of DNA and RNA. Annals of the New York Academy of Sciences, 2006, 1075, 282-287.	3.8	11
260	Non-invasive prenatal diagnosis of Down's syndrome. Lancet, The, 2007, 369, 1997.	13.7	11
261	Towards multi-cancer screening using liquid biopsies. Nature Reviews Clinical Oncology, 2020, 17, 525-526.	27.6	11
262	Fetal mitochondrial <scp>DNA</scp> in maternal plasma in surrogate pregnancies: Detection and topology. Prenatal Diagnosis, 2021, 41, 368-375.	2.3	11
263	Introduction to the Polymerase Chain Reaction. , 2006, 336, 1-10.		10
264	Technical Optimization of RhD Zygosity Determination by Real-Time Quantitative Polymerase Chain Reaction. Annals of the New York Academy of Sciences, 2006, 945, 156-160.	3.8	10
265	Development of extraction protocols to improve the yield for fetal RNA in maternal plasma. Prenatal Diagnosis, 2009, 29, 277-279.	2.3	10
266	Sequencing Analysis of Plasma Epstein-Barr Virus DNA Reveals Nasopharyngeal Carcinoma-Associated Single Nucleotide Variant Profiles. Clinical Chemistry, 2020, 66, 598-605.	3.2	10
267	Plasma RNA Integrity Analysis: Methodology and Validation. Annals of the New York Academy of Sciences, 2006, 1075, 174-178.	3.8	9
268	Single Cell and Plasma RNA Sequencing for RNA Liquid Biopsy for Hepatocellular Carcinoma. Clinical Chemistry, 2021, 67, 1492-1502.	3.2	9
269	Quantitative analysis of circulating cellâ€free Epstein–Barr virus (EBV) DNA levels in patients with EBVâ€associated lymphoid malignancies. British Journal of Haematology, 2000, 111, 239-246.	2.5	8
270	Fetal DNA in Maternal Plasma/Serum: The First 5 Years: Commentary on the article by Jimenez and Tarantal on page 18. Pediatric Research, 2003, 53, 16-17.	2.3	8

#	Article	IF	Citations
271	Clinical Applications of Plasma Epstein-Barr Virus DNA Analysis and Protocols for the Quantitative Analysis of the Size of Circulating Epstein-Barr Virus DNA., 2006, 336, 111-122.		8
272	Enrichment of fetal and maternal long cellâ€free DNA fragments from maternal plasma following DNA repair. Prenatal Diagnosis, 2019, 39, 88-99.	2.3	8
273	Circulating Cellâ€Free Epsteinâ€Barr Virus DNA Levels in Patients with EBVâ€Associated Lymphoid Malignancies. Annals of the New York Academy of Sciences, 2001, 945, 80-83.	3.8	7
274	Use of a Bone Marrow Transplantation Model System to Demonstrate the Hematopoietic Origin of Plasma S100B mRNA. Clinical Chemistry, 2007, 53, 1874-1876.	3.2	7
275	The Quest for Accurate Measurement of Fetal DNA in Maternal Plasma. Clinical Chemistry, 2011, 57, 522-523.	3.2	7
276	Tracing the tissue of origin of plasma DNA—feasibility and implications. Annals of the New York Academy of Sciences, 2016, 1376, 14-17.	3.8	7
277	Circulating nucleic acid analysis: diagnostic applications for acute pathologies. Acta Neurochirurgica Supplementum, 2005, 95, 471-474.	1.0	7
278	Jagged Ends on Multinucleosomal Cell-Free DNA Serve as a Biomarker for Nuclease Activity and Systemic Lupus Erythematosus. Clinical Chemistry, 2022, 68, 917-926.	3.2	7
279	Quantitative Subtyping of Hepatitis B Virus Reveals Complex Dynamics of Ymdd Motif Mutants Development during Long-Term Lamivudine Therapy. Antiviral Therapy, 2006, 11, 1041-1050.	1.0	7
280	Free Fetal DNA in Maternal Circulation. JAMA - Journal of the American Medical Association, 2004, 292, 2835.	7.4	6
281	Fetal nucleic acids in maternal blood: the promises. Clinical Chemistry and Laboratory Medicine, 2012, 50, 995-8.	2.3	6
282	The potential clinical utility of serial plasma albumin mRNA monitoring for the post-liver transplantation management. Clinical Biochemistry, 2013, 46, 1313-1319.	1.9	6
283	Noninvasive prenatal testing complicated by maternal malignancy: new tools for a complex problem. Npj Genomic Medicine, 2016, 1, 15002.	3.8	6
284	Circular RNAs as Urinary Biomarkers. Clinical Chemistry, 2019, 65, 1196-1198.	3.2	6
285	Screening of Fetal Chromosomal Aneuploidy by Noninvasive Prenatal Testing: From Innovation to Setting Public Health Agendas to Potential Impact on Other Fields. Clinical Chemistry, 2020, 66, 25-28.	3.2	6
286	Quantitative Assays for Telomerase: Means for Studying the End. Clinical Chemistry, 1998, 44, 2399-2400.	3.2	5
287	Clinical, Virologic and Immunologic Profiles of a Young Infant With Severe Acute Respiratory Syndrome. Pediatric Infectious Disease Journal, 2005, 24, 567-568.	2.0	5
288	Detrimental Effect of Formaldehyde on Plasma RNA Detection. Clinical Chemistry, 2005, 51, 1074-1076.	3.2	5

#	Article	IF	Citations
289	Automated extraction protocol for quantification of SARS-Coronavirus RNA in serum: an evaluation study. BMC Infectious Diseases, 2006, 6, 20.	2.9	5
290	Noninvasive fetal trisomy 21 detection using chromosome-selective sequencing: a variation of the molecular counting theme. Expert Review of Molecular Diagnostics, 2012, 12, 329-331.	3.1	5
291	Noninvasive Fetal Whole-Genome Sequencing from Maternal Plasma: Feasibility Studies and Future Directions. Clinical Chemistry, 2013, 59, 601-603.	3.2	5
292	Introduction to the Polymerase Chain Reaction. , 1998, 16, 3-10.		4
293	A simple and rapid approach for screening of SARS-coronavirus genotypes: an evaluation study. BMC Infectious Diseases, 2005, 5, 87.	2.9	4
294	Fetal Rhesus D mRNA Is Not Detectable in Maternal Plasma. Clinical Chemistry, 2005, 51, 2210-2211.	3.2	4
295	Investigation of the Genomic Representation of Plasma DNA in Pregnant Women by Comparative Genomic Hybridization Analysis: A Feasibility Study. Clinical Chemistry, 2005, 51, 2398-2401.	3.2	4
296	Molecular Diagnostics: At the Cutting Edge of Translational Research. Clinical Chemistry, 2009, 55, 601-601.	3.2	4
297	Advancing Laboratory Medicine through Innovation: A Tale of Six Inventors. Clinical Chemistry, 2012, 58, 502-510.	3.2	4
298	Noninvasive prenatal testing: Advancing through a virtuous circle of science, technology and clinical applications. Prenatal Diagnosis, 2021, 41, 1190-1192.	2.3	4
299	Nuclease deficiencies alter plasma cell-free DNA methylation profiles. Genome Research, 2021, 31, 2008-2021.	5.5	4
300	High-resolution analysis for urinary DNA jagged ends. Npj Genomic Medicine, 2022, 7, 14.	3.8	4
301	Setting Up a PCR Laboratory. , 1998, 16, 11-17.		3
302	Genomic Sequencing of the Severe Acute Respiratory Syndrome-Coronavirus., 2006, 336, 177-194.		2
303	Molecular Diagnostics: Going from Strength to Strength. Clinical Chemistry, 2020, 66, 1-2.	3.2	2
304	Biology and Diagnostic Applications of Cell-Free Fetal Nucleic Acids in Maternal Plasma. Nucleic Acids and Molecular Biology, 2010, , 147-166.	0.2	2
305	Enhanced cancer detection from cell-free DNA. Nature Biotechnology, 2022, , .	17.5	2
306	Artificial Restriction Fragment Length Polymorphism (A-RFLP) Analysis. , 1998, 16, 71-80.		1

#	Article	IF	CITATIONS
307	Methy-Pipe: An integrated bioinformatics data analysis pipeline for whole genome methylome analysis. , 2010, , .		1
308	Noninvasive Prenatal Testing for Genetic Diseases. , 2019, , 597-625.		1
309	Single-nucleotide polymorphism (SNP) of excision repair cross complementation group 1 (ERCC1) in nasopharynx cancer (NPC): A companion biomarker study to Hong Kong NPC Study Group 0502 trial Journal of Clinical Oncology, 2014, 32, 6029-6029.	1.6	1
310	Theranos Session at the 2016 AACC Annual Scientific Meeting & Expo: Expectations, Impressions, and Takeaways. journal of applied laboratory medicine, The, 2016, 1, 329-338.	1.3	1
311	Amplification from Archival Materials. , 1998, 16, 21-26.		0
312	Generation of Labeled Probes by PCR. , 1998, 16, 93-100.		0
313	PCR-Based Noninvasive Prenatal Diagnosis Using Fetal Cells in Maternal Circulation. , 1998, 16, 265-274.		0
314	PCR for the Detection of Minority DNA Populations. , 1998, 16, 101-108.		0
315	Prenatal detection of fetal Down's syndrome. Lancet, The, 2001, 357, 959.	13.7	0
316	FETAL NUCLEIC ACIDS IN MATERNAL PLASMA. Fetal and Maternal Medicine Review, 2006, 17, 125-137.	0.3	0
317	Nicht-invasive prĀ ¤ atale Diagnostik fetaler chromosomaler Aneuploidien mittels NukleinsĀ ¤ reanalyse des mýtterlichen Plasmas / Noninvasive prenatal diagnosis of fetal chromosomal aneuploidies by	0.6	0
318	Noninvasive Prenatal Diagnosis Using Next-Generation Sequencing., 2013,, 241-251.		0
319	Circulating Nucleic Acids for Prenatal Diagnostics. , 2018, , 283-294.		0
320	Fetal DNA in Maternal Plasma: An Amazing Two Decades. , 2018, , 3-5.		0
321	Laboratory Diagnosis., 2004,, 64-75.		0
322	Nucleic Acid Isolation., 2012, , 1231-1237.		0
323	Plasma Nucleic Acids. , 2012, , 1397-1411.		0
324	Abstract PL04-01: Screening for nasopharyngeal carcinoma using plasma Epstein-Barr virus DNA: Technological and clinical insights. , $2019, \ldots$		0

ARTICLE IF CITATIONS

325 Generation of Labeled Probes by Polymerase Chain Reaction., 0, , 127-133. 0